Unity Biotechnology, Inc. (UBX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Unity Biotechnology, Inc. (UBX) trades at $0.2001 with AI Score 47/100 (Grade C). Unity Biotechnology, Inc. is a biotechnology company focused on developing therapeutics for age-related diseases, particularly those affecting the eye. Market cap: $3.44M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 6, 2026Analyst Coverage for UBX: UBX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates UBX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
UBX: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Unity Biotechnology, Inc. (UBX) Healthcare & Pipeline Overview
Unity Biotechnology, Inc. is a biotechnology firm specializing in the research and development of therapeutics targeting age-related diseases. Their primary focus is on ophthalmologic conditions, with UBX1325, a drug candidate currently in Phase II clinical trials, leading their pipeline. The company operates in the competitive biotechnology sector, addressing unmet needs in age-related macular degeneration and diabetic macular edema.
What Is the Investment Thesis for UBX?
Unity Biotechnology's investment thesis hinges on the potential of its lead drug candidate, UBX1325, to address significant unmet needs in age-related macular degeneration and diabetic macular edema. Positive Phase II clinical trial results for UBX1325 could serve as a major catalyst, driving significant value appreciation. The company's pipeline of additional drug candidates, including UBX1967, UBX2050, and UBX2089, offers further upside potential, albeit with associated development risks. However, the company's negative profit margin of -1185.4% and small market capitalization present substantial risks. Successful navigation of clinical trials, regulatory approvals, and securing additional funding are critical for realizing the company's long-term potential. The company's gross margin of 36.6% suggests potential profitability if clinical trials are successful and products are commercialized.
Based on FMP financials and quantitative analysis
UBX Key Highlights
UBX1325 is in Phase II clinical trials for age-related eye diseases, including diabetic macular edema and age-related macular degeneration.
- The company has a gross margin of 36.6%, indicating potential for profitability upon successful commercialization of its drug candidates.
- Unity Biotechnology is developing UBX1967 for the treatment of ophthalmologic diseases.
- The company is also developing UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases.
- Unity Biotechnology is developing UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
Who Are UBX's Competitors?
UBX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are UBX's Key Strengths?
Novel senolytic technology platform.
- Pipeline of drug candidates targeting age-related diseases.
- Focus on unmet needs in ophthalmology and neurology.
- Experienced management team.
What Are UBX's Weaknesses?
Limited financial resources.
- Small market capitalization.
- Dependence on the success of UBX1325.
- High risk of clinical trial failures.
What Could Drive UBX Stock Higher?
Phase II clinical trial results for UBX1325 in diabetic macular edema.
- Phase II clinical trial results for UBX1325 in age-related macular degeneration.
- Development of UBX1967 for the treatment of ophthalmologic diseases.
- Development of UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases.
What Are the Key Risks for UBX?
Financial-distress signal — its Altman Z-Score of -26.38 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for UBX1325 or other drug candidates.
- Regulatory hurdles and delays in obtaining approvals for new therapeutics.
- Competition from other biotechnology and pharmaceutical companies.
- Difficulty securing additional funding to support research and development.
- Intellectual property challenges and patent disputes.
What Are the Growth Opportunities for UBX?
- Growth opportunity 1: Successful completion of Phase II clinical trials for UBX1325 represents a significant growth opportunity. Positive results could lead to partnerships with larger pharmaceutical companies for Phase III trials and eventual commercialization. The market for AMD and DME treatments is substantial, with projections estimating billions of dollars in annual sales. Securing regulatory approval and achieving market penetration could drive significant revenue growth for Unity Biotechnology.
- Growth opportunity 2: Expansion into new therapeutic areas beyond ophthalmology offers another avenue for growth. The development of UBX2089, targeting neurology indications, demonstrates the company's ambition to address a broader range of age-related diseases. Success in neurology could diversify the company's revenue streams and reduce its reliance on ophthalmology-focused products. The market for neurology therapeutics is also substantial and growing.
- Growth opportunity 3: Strategic partnerships and collaborations with other biotechnology and pharmaceutical companies could accelerate the development and commercialization of Unity Biotechnology's drug candidates. Collaborations can provide access to additional funding, expertise, and resources, increasing the likelihood of success. These partnerships could also expand the company's geographic reach and market access.
- Growth opportunity 4: Advancements in senolytic medicine, the core of Unity Biotechnology's approach, could unlock new therapeutic targets and opportunities. Continued research and development in this area could lead to the discovery of novel drug candidates with broad applications in age-related diseases. This could position Unity Biotechnology as a leader in the field of senolytic therapeutics.
- Growth opportunity 5: Securing additional funding through venture capital, public offerings, or grants is crucial for supporting the company's ongoing research and development efforts. Adequate funding will enable Unity Biotechnology to advance its pipeline of drug candidates through clinical trials and regulatory approvals. Access to capital is essential for sustaining the company's operations and achieving its long-term growth objectives.
What Are UBX's Competitive Advantages?
- Proprietary senolytic technology platform.
- Pipeline of novel drug candidates targeting unmet needs in age-related diseases.
- Intellectual property protection for its drug candidates and technologies.
- Expertise in the development of therapeutics for age-related diseases.
What Does UBX Do?
Unity Biotechnology, Inc., founded in 2009 and headquartered in South San Francisco, California, is a biotechnology company dedicated to developing therapeutics that slow, halt, or reverse diseases associated with aging. Originally named Forge, Inc., the company rebranded as Unity Biotechnology in January 2015, signaling a refined focus on age-related interventions. Their lead drug candidate, UBX1325, is currently undergoing Phase II clinical trials for the treatment of age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). This highlights their commitment to addressing significant unmet needs in ophthalmology. Beyond UBX1325, Unity Biotechnology is also developing UBX1967 for other ophthalmologic diseases, UBX2050, a human anti-Tie2 agonist monoclonal antibody targeting age-related eye diseases, and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. These diverse programs reflect a broader ambition to tackle aging-related pathologies beyond vision. The company's strategy centers on identifying and developing innovative therapies that can improve the healthspan of individuals, allowing them to live longer and healthier lives. With a small team of 16 employees, Unity Biotechnology operates with a lean structure, emphasizing focused research and development efforts to advance its pipeline.
What Products and Services Does UBX Offer?
- Develop therapeutics to slow, halt, or reverse diseases of aging.
- Focus on age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
- Conduct Phase II clinical trials for UBX1325, their lead drug candidate.
- Develop UBX1967 for the treatment of ophthalmologic diseases.
- Develop UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases.
- Develop UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
How Does UBX Make Money?
- Research and development of novel therapeutics.
- Out-licensing or partnering with larger pharmaceutical companies for late-stage development and commercialization.
- Securing funding through venture capital, public offerings, and grants.
- Focusing on senolytic medicines to target the underlying causes of aging-related diseases.
What Industry Does UBX Operate In?
Unity Biotechnology operates within the biotechnology industry, a sector characterized by high risk and high reward. The market for age-related disease therapeutics is substantial and growing, driven by an aging global population. Competition is intense, with numerous companies vying to develop innovative treatments for conditions like age-related macular degeneration and diabetic macular edema. Unity Biotechnology's focus on senolytic medicines and its pipeline of drug candidates position it to potentially capture a share of this expanding market. Success hinges on navigating the complex regulatory landscape and demonstrating clinical efficacy.
Who Are UBX's Key Customers?
- Patients suffering from age-related diseases, particularly those affecting the eye.
- Pharmaceutical companies seeking to expand their product portfolios with innovative therapeutics.
- Healthcare providers who prescribe and administer treatments for age-related diseases.
Forward Outlook
Wall Street analysts project Unity Biotechnology, Inc. revenue of about $6.2M for fiscal 2026, with EPS near $-0.82. The estimate reflects 4 contributing analysts.
UBX Valuation & Market Position
With a $3.44M market cap, Unity Biotechnology, Inc. sits in the micro-cap segment of the market. Relative to its peer group, UBX's quantitative score of 47/100 is below the peer average of 76/100.
Key Financial Metrics
Return on assets is -69.0%, showing how much profit it generates from its asset base. A current ratio of 2.62 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Unity Biotechnology, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -26.38 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Unity Biotechnology, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 15.8% above estimates on average.
Company Profile
Unity Biotechnology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Anirvan Ghosh. UBX has traded publicly since 2018.
UBX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Unity's long-term potential, indicating that management believes in the company's growth trajectory.
- Community sentiment has shifted positively, with discussions highlighting recent advancements in their aging-related therapies as a game changer.
- The increasing focus on biotechnology and longevity in the market has attracted attention, positioning Unity as a key player in an emerging sector.
- Recent collaborations and partnerships hint at expanding research opportunities, enhancing Unity's credibility and potential for breakthroughs.
Bear Case
- Concerns about the pace of clinical trials have surfaced, with some investors questioning the timeline for product commercialization.
- Market sentiment remains cautious due to the competitive landscape in biotechnology, where numerous players are vying for dominance.
- Recent discussions have noted skepticism about the company’s ability to deliver consistent results, impacting investor confidence.
- The overall volatility in biotech stocks creates uncertainty, leading some investors to adopt a more bearish outlook on Unity's near-term prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $1M | -$8M | -$0.50 |
Based on FMP financials and quantitative analysis
UBX Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Aug 16, 2019
UBX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for UBX.
Price Targets
Wall Street price target analysis for UBX.
UBX MoonshotScore
What does this score mean?
The MoonshotScore rates UBX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Anirvan Ghosh
Unknown
Anirvan Ghosh currently manages 16 employees at Unity Biotechnology, Inc. Additional background information regarding his career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive profile cannot be constructed at this time. Further research would be needed to provide a more detailed overview of his professional background.
Track Record: Due to the limited information available, it is not possible to assess Anirvan Ghosh's track record at Unity Biotechnology, Inc. Key achievements, strategic decisions, and company milestones under his leadership cannot be determined based on the provided data. Further research would be required to evaluate his performance and contributions to the company.
What Investors Ask About Unity Biotechnology, Inc. (UBX) — Healthcare
What does the AI Score mean for UBX?
UBX holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Unity Biotechnology, Inc. is a biotechnology company focused on developing therapeutics for age-related diseases, particularly those affecting the eye. Their lead drug candidate, UBX1325, is …
What does Unity Biotechnology, Inc. do?
Unity Biotechnology, Inc. is a biotechnology company focused on developing therapeutics to slow, halt, or reverse diseases of aging. Their primary focus is on age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). Their lead drug candidate, UBX1325, is currently in Phase II clinical trials for these conditions.
What do analysts say about UBX stock?
Analyst coverage of Unity Biotechnology, Inc. (UBX) is not available with the provided information. Key valuation metrics and growth considerations are unknown. Further research is needed to determine analyst consensus and recommendations. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. The company's small market capitalization and early-stage development status present significant risks.
What are the main risks for UBX?
Unity Biotechnology faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the success of UBX1325 and other drug candidates is uncertain. Regulatory hurdles and delays in obtaining approvals for new therapeutics could also impact the company's timeline and financial performance.
What are the key factors to evaluate for UBX?
Unity Biotechnology, Inc. (UBX) holds an AI score of 47/100 (low). Unity Biotechnology's investment thesis hinges on the potential of its lead drug candidate, UBX1325, to address significant unmet needs in age-related macular degeneration and diabetic macular edema. Not financial advice.
How frequently does UBX data refresh on this page?
UBX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven UBX's recent stock price performance?
Unity Biotechnology, Inc. (UBX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel senolytic technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider UBX overvalued or undervalued right now?
Unity Biotechnology, Inc. (UBX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research UBX before investing?
Before investing in Unity Biotechnology, Inc. (UBX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available.
- CEO background information is incomplete.
- Analyst ratings are unavailable.